Vertex Pharma (VRTX) Tops Q1 EPS by 4c; Reiterates Outlook
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $546.91 +0.44%
Revenue Growth %: +10.7%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +10.7%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.52, $0.04 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.07 billion.
GUIDANCE:
Vertex Pharma reiterates FY2022 revenue of $8.4-8.6 billion, versus the consensus of $8.58 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Adjust Monthly US Director's Cut List
- Designer Brands (DBI) PT Lowered to $6 at UBS
- Medtronic jumps on earnings beat and raised guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
